Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF-Reference-Cited by-同舟云学术

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF

Published:2009-11 Issue:11 Volume:84 Page:733-737
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Martin Mike G.,Augustin Kristan M.,Uy Geoffrey L.,Welch John S.,Hladnik Lindsay,Goyal Sagun,Tiwari Divya,Monahan Ryan S.,Reichley Richard M.,Cashen Amanda F.,Stockerl-Goldstein Keith,Westervelt Peter,Abboud Camille N.,DiPersio John F.,Vij Ravi

Publisher

Wiley

Subject

Hematology

Reference33 articles.

1. Acute myelogenous leukemia in older adults;Klepin;Oncologist,2009

2. Acute myeloid leukemia;Stone;Hematol Am Soc Hematol Educ Program,2004

3. Biology and management of relapsed acute myeloid leukaemia;Craddock;Br J Haematol,2005

4. Response to salvage therapy and survival after relapse in acute myelogenous leukemia;Keating;J Clin Oncol,1989

5. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia;Estey;Leuk Lymphoma,1993

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-05-17

2. Venetoclax: A Game Changer in the Treatment of Younger AML Patients?;Cancers;2023-12-22

3. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions;Bioengineering;2023-05-13

4. Consenso de leucemia mieloide aguda en México;Gaceta Médica de México;2023-03-28

5. Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia;Transplantation and Cellular Therapy;2022-05